Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages 1434-1444

  Groenendijk, Floris H ^a   Mellema, Wouter W ^b   Van Der Burg, Eline ^a   Schut, Eva ^a   Hauptmann, Michael ^a   Horlings, Hugo M ^a   Willems, Stefan M ^a,c   Van Den Heuvel, Michel M ^a   Jonkers, Jos ^a   Smit, Egbert F ^b   Bernards, René ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

AMP activated protein kinase; Metformin; Non small cell lung cancer; Salicylate; Sorafenib

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PHOSPHOTRANSFERASE; PROTEIN CAMKK2; PROTEIN KINASE LKB1; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE KINASE; CARBANILAMIDE DERIVATIVE; KRAS PROTEIN, HUMAN; NICOTINAMIDE; ONCOPROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; TARGET OF RAPAMYCIN KINASE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MONOTHERAPY; MOUSE; MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE K RAS; PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DRUG SCREENING; FEMALE; GENETICS; LUNG NEOPLASMS; METABOLISM; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE KINASE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HUMANS; LUNG NEOPLASMS; METFORMIN; MICE; MICE, INBRED BALB C; MUTATION; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961386372     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29113     Document Type: Article

References (35)

1. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 2011;13:1016-23.
2. Hemminki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
3. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
4. Gill RK, Yang SH, Meerzaman D, et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 2011;30:3784-91.
5. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
6. Dowling RJ, Niraula S, Stambolic V, et al. Metformin in cancer: translational challenges. J Mol Endocrinol 2012;48:R31-R43.
7. Pierotti MA, Berrino F, Gariboldi M, et al. Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multifaceted effects. Oncogene 2013;32:1475-87.
8. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9:1092-9.
9. Huang X, Wullschleger S, Shpiro N, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J 2008;412:211-21.
10. Hardie DG. The LKB1-AMPK pathway-friend or foe in cancer? Cancer Cell 2013;23:131-2.
11. Fryer LG, Parbu-Patel A, Carling D. The Antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002;277:25226-32.
12. Sun W, Lee TS, Zhu M, et al. Statins activate AMP-activated protein kinase in vitro and in vivo. Circulation 2006;114:2655-62.
13. Hawley SA, Fullerton MD, Ross FA, et al. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012;336:918-22.
14. Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
15. Chen G, Xu S, Renko K, Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J Clin Endocrinol Metab 2012;97:E510-E20.
16. Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 2009;69:7507-11.
17. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res 2011;71:3196-201.
18. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009;27: 3297-302.
19. Rocha GZ, Dias MM, Ropelle ER, et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin Cancer Res 2011;17:3993-4005.
20. Martin MJ, Hayward R, Viros A, et al. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov 2012;2:344-55.
21. Dingemans AM, Mellema WW, Groen HJ, et al. A Phase II Study of Sorafenib in Patients with Platinum-Pretreated, Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer with a KRAS Mutation. Clin Cancer Res 2013;19:743-51.
22. Chiou JF, Tai CJ, Wang YH, et al. Sorafenib induces preferential apoptotic killing of a drug-and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther 2009;8:1904-13.
23. Coriat R, Nicco C, Chereau C, et al. Chaussade S, Goldwasser F, Batteux F. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 2012;11:2284-93.
24. Mungai PT, Waypa GB, Jairaman A, et al. Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol 2011;31:3531-45.
25. Alexander A, Cai SL, Kim J, et al. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci USA 2010;107:4153-8.
26. Rahmani M, Davis EM, Crabtree TR, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007;27:5499-513.
27. Fumarola C, Caffarra C, La Monica S, et al. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res Treat 2013;141:67-78.
28. Pignochino Y, Dell'Aglio C, Basirico M, et al. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res 2013;19:2117-31.
29. Eum KH, Ahn SK, Kang H, et al. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrugresistant cells. Mol Cell Biochem 2013;372:65-74.
30. Ling S, Feng T, Ke Q, et al. Wang L. Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep 2014;31:2611-8.
31. Fleischman A, Shoelson SE, Bernier R, et al. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care 2008;31:289-94.
32. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6.
33. Shackelford DB, Abt E, Gerken L, et al. LKB1 Inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 2013;23:143-58.
34. Mazzone PJ, Rai H, Beukemann M, et al. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer 2012;12:410.
35. Birsoy K, Possemato R, Lorbeer FK, et al. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 2014;508:108-12.